7月16日 - ** 生物技术公司Jasper Therapeutics（JSPR.O）的股价在盘后交易中上涨43%，至1.12美元
** JSPR表示，已通过全股票交易完成了对私营公司Kira Pharmaceuticals的收购
** 合并后的公司将专注于开发免疫相关疾病的治疗方案，包括Kira用于治疗罕见血液疾病和肾脏疾病的领先候选药物KP-104、Jasper的briquilimab项目以及Kira处于临床前阶段的KP-701抗体项目
** 若Jasper能在2028年12月31日前获得并变现briquilimab的优先审查凭证，现有Jasper股东将获得一份不可转让的CVR，该凭证与潜在的3000万美元总付款挂钩
** Jasper表示，Kira已将其两个候选药物KP-301和KP-402授权给Mirador Therapeutics，获得1200万美元预付款，外加潜在的研发和销售里程碑付款
** 截至上一交易日收盘，JSPR股票今年以来累计下跌57%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.